Modality
Cell Therapy
MOA
WEE1i
Target
FXIa
Pathway
Fibrosis
FTDPancreatic Ca
Development Pipeline
Preclinical
~May 2018
→ ~Aug 2019
Phase 1
Nov 2019
→ Jan 2027
Phase 1Current
NCT08341595
2,951 pts·Pancreatic Ca
2019-11→2027-01·Terminated
NCT03641361
2,579 pts·Pancreatic Ca
2025-12→TBD·Active
5,530 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-01-2710mo awayPh2 Data· Pancreatic Ca
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027
P1/2
Termina…
P1/2
Active
Catalysts
Ph2 Data
2027-01-27 · 10mo away
Pancreatic Ca
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08341595 | Phase 1/2 | Pancreatic Ca | Terminated | 2951 | Biomarker |
| NCT03641361 | Phase 1/2 | Pancreatic Ca | Active | 2579 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa |